There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX – Research Report) and Editas Medicine (EDIT – Research Report) with bullish sentiments.
Springworks Therapeutics (SWTX)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Springworks Therapeutics today. The company’s shares closed last Monday at $18.35, close to its 52-week low of $17.66.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 11.5% and a 64.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Rocket Pharmaceuticals, and Orchard Therapeutics.
Springworks Therapeutics has an analyst consensus of Moderate Buy.
Editas Medicine (EDIT)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Editas Medicine, with a price target of $55.00. The company’s shares closed last Monday at $21.28.
According to TipRanks.com, Livshits is a 3-star analyst with an average return of 6.2% and a 52.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Editas Medicine is a Moderate Buy with an average price target of $55.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.